New Nonhormonal Hot Flash Recs; Global Plastics Treaty; SGLT2 & Lower Cancer Risk?

The North American Menopause Society released an updated position statement on the latest nonhormonal hot flash treatment options. (Menopause)

A longitudinal analysis showed that while kids with type 1 diabetes rapidly progressed to absolute insulin deficiency, many adolescents and adults had residual random serum C-peptide decades after diagnosis. (The Lancet Diabetes & Endocrinology)

In order to protect the public from harmful endocrine-disrupting chemicals, the Endocrine Society called for a global plastics treaty.

How much risk does the antidiabetic and weight-loss drug semaglutide (Ozempic, Wegovy) pose to pregnancy? (Fox News)

Patients with diabetes on an SGLT2 inhibitor saw a 21% lower risk for developing cancer compared with those not taking these drugs. (Journal of Diabetes and its Complications)

No surprise here: teens living in more “obesogenic” places were more likely to see their BMI increase over time, according to a natural experiment study. (JAMA Pediatrics)

Postmenopausal women who took an oral form of estrogen-only hormone therapy had an increased risk of hypertension compared with those who took either transdermal or vaginal estrogen, a cohort study showed. (Hypertension)

A CDC report found that the rate of prepregnancy diabetes among U.S. mothers increased 27% from 2016 to 2021. (National Vital Statistics Reports)

States are suing 3M and DuPont over allegations of toxic “forever chemicals” in drinking water. (CNBC)